Vanguard Investments Australia
VRDN icon

Vanguard Investments Australia’s Viridian Therapeutics VRDN Stock Holding History

Vanguard Investments Australia’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Hold
16,170
– – ﹤0.01% 1932
2026
Q1 		$316K Buy
+16,170
New +$480K ﹤0.01% 1814

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Investments Australia's VRDN Position: Q2 2026 in Review

Vanguard Investments Australia held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 16,170 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #1932.

Vanguard Investments Australia first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. The position peaked at $316K in Q1 2026. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Vanguard Investments Australia held 16,170 shares of Viridian Therapeutics worth $297K as of Q2 2026.
  • Vanguard Investments Australia left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1932 holding.
  • Vanguard Investments Australia first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Investments Australia's Viridian Therapeutics position peaked at $316K in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.